https://www.siliconvalley.com/2024/11/12/bay-areas-23andme-cuts-40-of-its-workforce-and-discontinues-therapeutics-division/ > NEW YORK  — 23andMe is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs. > The latest restructuring efforts were announced by 23andMe on Monday. The company said it plans to wind down ongoing clinical trials “as quickly as practical” — and that it was currently evaluating “strategic alternatives” for assets related to its drug development and research programs, which include studies on potential cancer treatments.